Slide 1: Address by Chairman John Shine and Slides for MD/CEO Paul Perreault
For personal use only For immediate release 17 October 2018 Address by Chairman John Shine AC and Slides for MD/CEO Paul Perreault CSL 2018 Annual General Meeting Please find attached the Chairman’s Address and Managing Director’s slides to be presented at CSL’s Annual General Meeting which commence
Slide 2: Chairman's address: meeting opening
For personal use only Page 2 17 October 2018 CSL Limited AGM 2018 Chairman’s address Ladies and Gentlemen, It is the appointed time for the commencement of the Annual General Meeting of CSL Limited, a quorum is present and I declare the meeting open. My name is John Shine and as Chairman of CSL Limi
Slide 3: Chairman's address: FY2018 performance and capital management
For personal use only Page 3 17 October 2018 I would now like to provide you with some of the highlights of our performance for the year ended 30 June 2018. I hope that you have taken the opportunity to read our most recent Annual Report, copies of which are available here and also on CSL’s website.
Slide 4: Chairman's address: dividends and corporate responsibility
For personal use only Page 4 17 October 2018 shareholders on 12 October. This brought total ordinary dividends for the year to US$1.72 per share or approximately A$2.28 per share, an increase of 30% in Australian dollars. The reason this dividend is unfranked is that there are insufficient Australia
Slide 5: Chairman's address: community, environment and safety
For personal use only Page 5 17 October 2018 We are also very proud of our support for communities in Papua New Guinea. We entered a new three-year partnership to help save the lives of people bitten by venomous snakes in PNG, with the PNG Department of Health, the Australian High Commission, and th
Slide 6: Chairman's address: awards and shareholder communication
For personal use only Page 6 17 October 2018 with the life-threatening swelling disease known as hereditary angioedema, and Healthcare Innovator of the Year by the Philadelphia Business Journal. CSL is committed to communicating effectively with our key stakeholders, including shareholders. In addit
Slide 7: Chairman's address: board renewal
For personal use only Page 7 17 October 2018 As is evidenced by the strong field of proposed new appointments to the CSL Board, your Directors have been very focussed on Board renewal over the past 12 months and we have put a great deal of work into ensuring that we have the best possible Directors
Slide 8: Chairman's address: research and development investment
For personal use only Page 8 17 October 2018 As a scientist, I am particularly proud of the company’s commitment to a continual investment into research and development, which has increased from $370m in 2012 to $702m in 2018 – a 90 percent increase during my time as Chair. Innovation is at the hear
Slide 9: Chairman's closing remarks
For personal use only Page 9 17 October 2018 It has been an honour to serve as your Chairman for the past seven years and I thank you for your support. I now call on Paul to present a more detailed review of the Company’s operations, including our research and development portfolio. Professor John S
Slide 10: CSL Limited 2018 Annual General Meeting
For personal use only CSL Limited 2018 Annual General Meeting 17 October 2018 CEO – Paul Perreault 1 | Driven by Our Promise™
Slide 11: Legal Notice
For personal use only Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and produ
Slide 12: Delivering on Strategy
For personal use only Delivering on Strategy Growth Innovation People & Culture • Ig sales +11%1 • PRIVIGEN® approved for • Workforce +15% • IDELVION® exceeded forecast CIDP in US • Forbes Magazine Top 50 • Specialty Products +24%1 • HIZENTRA® approved for employer in the world - KCENTRA® & HAEGARDA
Slide 13: CSL Behring Sales FY18 Growth
For personal use only CSL Behring Sales FY18 Growth Therapeutic Group Region Sales % 18% Therapy $m Change1 EM 9% Immunoglobulins 3,145 11% Haemophilia 1,113 5% North 12% America 12% Asia Pac 46% Albumin 921 7% 17% US$6.7b Specialty 1,490 24% Other 9 Total 6,678 11% EU 28% 8% 1. Growth percentages s
Slide 14: Efficiency
For personal use only Efficiency Efficiency CSL PLASMA MANUFACTURING • Total CSL collection centres 206 • Group wide capital projects on track - 27 centres opened during FY18 - Unmatched in the industry - 35% of total US centre openings in FY18 • New Donor Management System delivering faster donatio
Slide 15: Innovation: Transplant
For personal use only Innovation Innovation No. of US Patients Undergoing Transplant Annually TRANSPLANT Compared With No. of Patients on the Waiting List • Emerging franchise 140,000 • High unmet need 120,000 100,000 • Leverages existing products 80,000 100,000 • Vitaeris collaboration 60,000 50,00
Slide 16: Innovation: CSL112, CSL730, Gene Therapy
For personal use only Innovation Innovation CSL112 CSL730 GENE THERAPY • Phase 3 study • Fc Multimer: • Calimmune acquisition commenced: - Provides improved • Proprietary stem cell - ~17,400 patients target binding gene therapy platform - 40 countries • Phase 1 trial • Differentiating • First patien
Slide 17: Seqirus Revenue FY18
For personal use only Seqirus Revenue FY18 Seqirus $m Category Region 1,200 20% 1,000 +30%1 EM 6% 3PL Other 800 Fluad 600 North 78% TIV 11% (ADJ 3PL) Asia Pac US$1.1b America 22% 61% 400 QIV 200 Pandemic EU 11% 0 FY17 FY17a FY18 Switch to QIV & Fluad Pandemic earnings growth 6% 1. Growth shown at co
Slide 18: Outlook for FY19
For personal use only Outlook for FY191 Reaffirmed • Continued strong demand for plasma and recombinant products • Margin growth from plasma product mix shift, specialty and NPAT ~$1,880m recombinant products growth & conclusion of HELIXATE® supply to $1,950m2 • CSL's collections growth expected to
Slide 19: Contact
For personal use only CSL Limited Contact InvestorRelations@csl.com.au 10 | Driven by Our Promise™